This talk will cover recent clinical trials presented at the ADA in 2019 that have an impact on the management of diabetes, such as cardiovascular outcomes trials and the first oral GLP-1 RA phase 3 data. The faculty will take you through the latest guidelines from the ADA regarding the management of type 2 diabetes and describe how recent clinical trial data has been integrated in to these guidelines. After this meeting review, you will be equipped to manage type 2 diabetes based on these guidelines. Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on February 7, 2020, and they are subject to change as new information is published.

What do primary care providers need to know about diabetes, atrial fibrillation, and heart failure? Dr. Matthew Freeby will address topics related to current type 2 diabetes care, with focus on education, medications and newer technologies. Dr. Karol Watson will discuss treatment and prevention of atrial fibrillation, and Dr. Jon Kobashigawa will discuss common questions about heart failure including risk factors, treatment options, lifestyle changes and prevention.

Diabetes management is challenging, and the ever-changing management guidelines and pharmacologic options add to this complexity. Join this panel discussion, led by a primary care clinician, endocrinologist and nephrologist as they review best practices in diabetes management with a focus on new updates and practical strategies to incorporate into your practice.

This session will cover some new data regarding treatment of type 2 diabetes: the GRADE study, SURPASS phase 3 program, the STEP program for treatment of obesity. It will also provide an update on studies using SGLT2 inhibitors and GLP 1 receptor agonists in people with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease.

Practice-changing updates to the medical literature that are hot off the presses! Join Dr. Pam Kushner to discuss important changes in the 2021 ADA guidelines and examine recently published research on atrial fibrillation, lipids, reducing cardiovascular risk, coconut oil, patient communication, and much more!

Maximum 50 words to introduce the activity The percentage of individuals with T2D achieving A1C <7% worsened from 2015-2018. Therapeutic inertia—failure to initiate or intensify treatment in a timely manner—is largely responsible for this problem. This program will support PCPs in overcoming therapeutic inertia through timely initiation and advancement of treatment with GLP-1 RAs and review guideline updates that support use of GLP-1 RA early in the treatment paradigm.

What do primary care providers need to know about wound care and the diabetic foot? Join infectious disease expert Richard Hamill, and internist Edward Lee Poythress, as they review important questions they get asked about these topics!

The percentage of individuals with T2D achieving A1C <7% worsened from 2015-2018. Therapeutic inertia—failure to initiate or intensify treatment in a timely manner—is largely responsible for this problem. This program will support PCPs in overcoming therapeutic inertia through timely initiation and advancement of treatment with GLP-1 RAs.

You know that insulin therapy is an important tool in improving quality of life and health outcomes for your patients with diabetes, but are you familiar with the expanding array of diabetes technology that can play an important role in improving insulin delivery and management? Do you know how to optimally use these tools? After this activity, you’ll be able to interpret continuous glucose monitoring data to improve time-in-range, minimize hypoglycemia, and reduce postprandial glycemic excursions. Don’t miss this opportunity to learn how to incorporate diabetes technology into clinical practice to optimize insulin management, bolster patients’ confidence in self-management of their diabetes, and, ultimately, improve health outcomes.

Given that 9 out of 10 people with diabetes also suffer from overweight or obesity, it is important for PCPs to take a holistic approach to treatment rather than solely a glucocentric approach. This activity helps you understand the benefits of weight loss as a key therapeutic strategy in the treatment of type 2 diabetes mellitus (T2DM) and the importance of early treatment intensification to improve long-term outcomes. You’ll also walk away from this session with a firm grasp of the role incretins play in the pathophysiology of T2DM, obesity, and other metabolic conditions and the latest clinical trial evidence behind incretin-based agents.